Amgen Seeks FDA Approval for First Biosimilar of Humira
Amgen Inc. AMGN announced the submission of a biologics license application (BLA) seeking FDA approval for ABP 501, a biosimilar version of AbbVie Inc.’s ABBV best-selling drug, Humira. The application is Amgen’s first BLA submitted under the 351(k) biosimilar pathway […]